ACLARION INC (ACON)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$2.35+2.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · ACON
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -66.2% |
| Our one-year growth estimate | diamond | 8.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 74.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 21 industry peers · Company calendar date is not available
ACON — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-03-19
Material Modification to Rights of Security Holders. On March 19, 2026, the board of directors (the “ Board ”) of Aclarion, Inc., a Delaware corporation (the “ Company ”), adopted a stockholder rights agreement and declared (i) a dividend of one right (a “ Right ”) for each outstanding share of Company common stock, par value $0.00001 per share (“ Common Stock ”), to stockholders of record at the close of business on March 30, 2026 (the “ Record Date ”) and (ii) a dividend of the aggregate nu…
Why it matters: More income is key for Aclarion's finances. It helps the company grow in the future.
Supportive ifQ2 operating income shows a reduction in losses compared to -$2,986,941 in Q1.
Worry ifIncome is still negative or worse than in Q1.
Why it matters: The share buyback plan shows Aclarion cares about its shareholders. It may help the stock price.
Supportive ifAclarion will complete at least $1 million in share buybacks in the next six months.
Worry ifNo share repurchases are reported within the next six months.
Why it matters: Updates on the buyback program may show confidence in the company's value and health.
Supportive ifThe company announces it has finished the buyback program or made good progress.
Worry ifNo updates or signs of share buybacks happening in the next quarter.
Why it matters: The CLARITY trial is important for Aclarion. Good results could increase trust in Nociscan.
Supportive ifAclarion shares good early results from the CLARITY trial.
Worry ifThe trial faces delays or reports negative results.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$247 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $861 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,915 loss on $10,000 · 79.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Successful M&A could boost growth and improve investor confidence in Aclarion.
Supportive ifAclarion has finished an acquisition. This helps its position in the market.
Worry ifNo M&A activity occurs or plans are delayed beyond the next quarter.
Why it matters: M&A could drive growth for Aclarion. Progress signals confidence in future plans.
Supportive ifA specific acquisition or merger deal will be announced in the next quarter.
Worry ifNo M&A announcements or updates in the next quarter.
Why it matters: Better operating income is important for Aclarion's finances. It shows they manage costs well.
Supportive ifOperating income turns positive. It also improves a lot from last quarter.
Worry ifOperating income stays negative or gets worse in the next quarter.
Why it matters: Successful M&A could drive growth and improve market position for Aclarion.
Supportive ifA completed acquisition was announced. It adds value and revenue.
Worry ifNo M&A announcements or progress reported in the next quarter.
Why it matters: Better operating income is key for Aclarion's finances. It shows improved cost control and growth.
Supportive ifAclarion says its operating income is less negative than -$2 million in Q2 2026.
Worry ifOperating income gets worse or stays below -$3 million in Q2 2026.